Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- New Parkinson’s Disease Treatment Nouriast Approved: Kyowa Kirin
March 27, 2013
- FD Treatment Acofide Approved: Zeria, Astellas
March 27, 2013
- Otsuka Receives Approval for DPP-4 Inhibitor Onglyza, to Transfer Marketing Rights to Kyowa Kirin
March 27, 2013
- Takeda Announces Full Cancellation of Correction Notice Based on Transfer Pricing Tax System; 15.2 Billion Yen Refund Expected
March 27, 2013
- Marc Dunoyer Steps Down as Chairman of GSK K.K.
March 26, 2013
- Terumo Launches Cancer Pain Treatment Methapain
March 26, 2013
- Takeda Files NDA for Malignant Lymphoma Treatment Brentuximab Vedotin in Japan
March 26, 2013
- JAK Inhibitor Xeljanz Approved for RA: Pfizer Japan
March 26, 2013
- Regtect Approved for Supporting Maintenance of Abstinence in Patients with Alcohol Dependence: Nippon Shinyaku
March 26, 2013
- Daiichi Sankyo Aims for Approval of Enbrel Biosimilar in FY2016: President Nakayama
March 26, 2013
- Daiichi Sankyo’s Osteoporosis Treatment Pralia Approved
March 26, 2013
- New Settai Rules Halfway to Establishment; Some in Industry Want Further Rules as Well
March 26, 2013
- Astellas Ties Up with Tokyo Tech and Nagasaki University to Research Anti-Dengue Virus Treatment
March 25, 2013
- Daiichi Sankyo Mulls Biz Platform after Olmesartan LOE: New 5 Year Plan
March 25, 2013
- Takeda Returns Global Rights to NPS Pharmaceuticals for Preotact and Revestive
March 25, 2013
- Israeli-Originated High-Techs Highlighted at Israel Life Science Forum 2013
March 25, 2013
- Merck Serono to Develop Anticancer Drugs for Asian Patients at R&D Hub in Tokyo
March 22, 2013
- New Product Launches “On Track,” Sales Brisk: Otsuka Holdings Pres. Higuchi
March 22, 2013
- SSRI Predicts SGLT-2 Inhibitor Market to Grow to around 60 Billion Yen in 5th Year after Launch
March 22, 2013
- Japan Pharmas Accelerating Drives to Set Up Medical Affairs Units
March 21, 2013
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…